These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 29588357

  • 1. Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam.
    Tamma PD, Fan Y, Bergman Y, Sick-Samuels AC, Hsu AJ, Timp W, Simner PJ, Prokesch BC, Greenberg DE.
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29588357
    [Abstract] [Full Text] [Related]

  • 2. Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis.
    Daccò V, Claut L, Piconi S, Castellazzi L, Garbarino F, Teri A, Colombo C.
    Transpl Infect Dis; 2019 Jun; 21(3):e13082. PubMed ID: 30892778
    [Abstract] [Full Text] [Related]

  • 3. Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam.
    Los-Arcos I, Len O, Martín-Gómez MT, González-López JJ, Saéz-Giménez B, Deu M, Nuvials X, Ferrer R, Román A, Gavaldà J.
    Infection; 2019 Apr; 47(2):289-292. PubMed ID: 30565008
    [Abstract] [Full Text] [Related]

  • 4. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates.
    Zeiser ET, Becka SA, Wilson BM, Barnes MD, LiPuma JJ, Papp-Wallace KM.
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [Abstract] [Full Text] [Related]

  • 5. Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series.
    Spoletini G, Etherington C, Shaw N, Clifton IJ, Denton M, Whitaker P, Peckham DG.
    J Antimicrob Chemother; 2019 May 01; 74(5):1425-1429. PubMed ID: 30649419
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.
    Van Dalem A, Herpol M, Echahidi F, Peeters C, Wybo I, De Wachter E, Vandamme P, Piérard D.
    Antimicrob Agents Chemother; 2018 Sep 01; 62(9):. PubMed ID: 29914964
    [Abstract] [Full Text] [Related]

  • 7. Ceftazidime plasma concentration in a patient with cystic fibrosis treated with ceftazidime/avibactam plus trimethoprim/sulfametoxazole for Bulkholderia cepacia reacutization.
    Saffioti C, Barco S, Cangemi G, Mesini A, Casciaro R, Cresta F, Castellani C, Bandettini R, Morelli P, Castagnola E.
    J Chemother; 2019 Sep 01; 31(7-8):436-438. PubMed ID: 31583970
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Susceptibility of Burkholderia cepacia Complex to Ceftazidime/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients.
    Schaumburg F, Idelevich EA, Mellmann A, Kahl BC.
    Microb Drug Resist; 2022 May 01; 28(5):545-550. PubMed ID: 35512733
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA, Smith TT, MacVane SH.
    Int J Antimicrob Agents; 2018 Apr 01; 51(4):629-635. PubMed ID: 29408227
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    Massip C, Mathieu C, Gaudru C, Miaut V, Floch P, Oswald E, Segonds C, Guet-Revillet H.
    J Antimicrob Chemother; 2019 Feb 01; 74(2):525-528. PubMed ID: 30312409
    [No Abstract] [Full Text] [Related]

  • 16. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Enterobacteriales Coresistant to Carbapenems and Polymyxins.
    Guimarães T, Nouér SA, Martins RCR, Perdigão Neto LV, Martins WMBS, Narciso Barbosa AC, Ferreira ALP, Costa SF, Gales AC.
    Antimicrob Agents Chemother; 2019 Oct 01; 63(10):. PubMed ID: 31358592
    [Abstract] [Full Text] [Related]

  • 17. Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.
    Becka SA, Zeiser ET, LiPuma JJ, Papp-Wallace KM.
    Antimicrob Agents Chemother; 2021 Oct 18; 65(11):e0133221. PubMed ID: 34370574
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.